Journal: The Journal of Immunology Author Choice
Article Title: Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections
doi: 10.1093/jimmun/vkaf055
Figure Lengend Snippet: Assessment of complement deposition and complement mediated killing induced by CTX-09. (A) C3b deposition was measured by incubating E. coli ATCC 25922 expressing green fluorescent protein (GFP) with 50% human serum (HS) and the indicated concentrations of CTX-09. The fold change relative to vehicle control was calculated for each CTX-09 concentration. (B) Fluorescence microscopy images comparing C3b deposition using PE-labeled anti-C3b antibody, for bacteria + 50% HS or 50% HS + 2.5 µM CTX-09. GFP= E. coli ATCC 25922; PE= C3b. Scale bar (white) = 100 µm. (C) Antibody-mediated complement deposition was assessed by measuring C1q and C3b deposition on E. coli ATCC 700973 after incubation with 20% HS + CTX-09 or Polymyxin B (PMB). Baseline = Bacteria incubated in 20% HS only. (D) Flow cytometry dot plots showing a CTX-09-mediated increase in C1q+C3b+ E. coli ATCC 700973 cells (upper right quadrant) vs 20% HS alone and 20% HS supplemented with 20 µM CTX-09. (E) Complement dependent cytotoxicity (CDC) was determined by measuring E. coli ATCC 700973 CFU concentrations following incubation with 20% HS and indicated concentrations of CTX-09. LOD, limit of detection. (F) Antibody dependent CDC was confirmed by comparing reductions in bacterial counts following incubation with either 20% HS, 20 µM CTX-09, or 20% HS + 20 µM CTX-09. LOD, limit of detection. Distribution of data displayed as bars representing mean or geometric mean ± SD with individual points plotted, or as line with points representing geometric mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 using 2-way ANOVA with Šídák's multiple comparisons ( n = 4) or 1-way ANOVA with Holm-Šídák's multiple comparisons ( n = 3–6).
Article Snippet: E. coli ATCC 700973, E. coli ATCC 25922–GFP, and P. aeruginosa ATCC 27853 were purchased from LGC standards; the remaining strains for in vitro and in vivo testing were purchased from UK Health Security Agency culture collections (see for more details on the above strains).
Techniques: Expressing, Control, Concentration Assay, Fluorescence, Microscopy, Labeling, Bacteria, Incubation, Flow Cytometry